U.S. markets closed
  • S&P Futures

    3,395.50
    +2.00 (+0.06%)
     
  • Dow Futures

    27,608.00
    +27.00 (+0.10%)
     
  • Nasdaq Futures

    11,493.50
    +1.25 (+0.01%)
     
  • Russell 2000 Futures

    1,603.80
    +1.70 (+0.11%)
     
  • Crude Oil

    38.68
    +0.12 (+0.31%)
     
  • Gold

    1,910.30
    +4.60 (+0.24%)
     
  • Silver

    24.59
    +0.17 (+0.70%)
     
  • EUR/USD

    1.1822
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    0.8010
    -0.0400 (-4.76%)
     
  • Vix

    32.46
    +4.91 (+17.82%)
     
  • GBP/USD

    1.3035
    +0.0014 (+0.11%)
     
  • USD/JPY

    104.7100
    -0.1250 (-0.12%)
     
  • BTC-USD

    13,114.30
    +5.52 (+0.04%)
     
  • CMC Crypto 200

    261.27
    -2.15 (-0.81%)
     
  • FTSE 100

    5,792.01
    -68.27 (-1.16%)
     
  • Nikkei 225

    23,428.70
    -65.64 (-0.28%)
     

Introducing Nektar Therapeutics (NASDAQ:NKTR), A Stock That Climbed 84% In The Last Three Years

Simply Wall St

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks, you could make more than that. For example, the Nektar Therapeutics (NASDAQ:NKTR) share price is up 84% in the last three years, clearly besting the market return of around 36% (not including dividends).

View our latest analysis for Nektar Therapeutics

Given that Nektar Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

Nektar Therapeutics's revenue trended up 42% each year over three years. That's much better than most loss-making companies. The share price rise of 23% per year throughout that time is nice to see, and given the revenue growth, that gain seems somewhat justified. So now might be the perfect time to put Nektar Therapeutics on your radar. A window of opportunity may reveal itself with time, if the business can trend to profitability.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

NasdaqGS:NKTR Income Statement, December 10th 2019
NasdaqGS:NKTR Income Statement, December 10th 2019

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Nektar Therapeutics stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

Nektar Therapeutics shareholders are down 37% for the year, but the market itself is up 21%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 9.8%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. Investors who like to make money usually check up on insider purchases, such as the price paid, and total amount bought. You can find out about the insider purchases of Nektar Therapeutics by clicking this link.

Nektar Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.